ABSTRACT:
Cardiovascular Disease (CVD) is not a single disease while it’s a combination of different diseases which involve the heart and blood vessel problem; Coronary Artery Disease (CAD), Myocardial Infraction (MI), Congenital Heart Disease, Deep Vein thrombosis Disease and many more. CVD is causing millions of death every year across the world and increasing its count and financial burden annually. Conventional methods, medicine, and surgery are being utilized to cure this fatal disease which can subdue the effect of disease but not showing the promising response for the long term. After the emergence of stem cell as a regenerative medicine, its potential is being utilized by different research to cure different non- curable diseases and also raise the hope to fight with CVD. This paper will provide the information of stem cell, its types, its role to cure CVD, and delivery methods into patient to provide cure from CVD.
Cite this article:
Jaspreet Singh, Sanjeev Singh. Stem Cell as a hope for the treatment of cardiovascular diseases. Research J. Pharm. and Tech. 2020; 13(8):3992-3998. doi: 10.5958/0974-360X.2020.00706.4
Cite(Electronic):
Jaspreet Singh, Sanjeev Singh. Stem Cell as a hope for the treatment of cardiovascular diseases. Research J. Pharm. and Tech. 2020; 13(8):3992-3998. doi: 10.5958/0974-360X.2020.00706.4 Available on: https://rjptonline.org/AbstractView.aspx?PID=2020-13-8-79
REFERENCES:
1. Ke C, Gupta R, Xavier D, Prabhakaran D, Mathur P, Kalkonde YV, Kolpak P, Suraweera W, Jha P, Allarakha S, Basavarajappa D. Divergent trends in ischaemic heart disease and stroke mortality in India from 2000 to 2015: a nationally representative mortality study. The Lancet Global Health.2018;6(8):914-23.
2. Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, Bravata DM, Dai S, Ford ES, Fox CS, Fullerton HJ. Heart disease and stroke statistics--2012 update: a report from the American Heart Association. Circulation. 2012;125(1):2-20.
3. https://www.who.int/cardiovascular_diseases/en/
4. Shah B, Mathur P. Surveillance of cardiovascular disease risk factors in India: the need and scope. The Indian journal of medical research. 2010;132(5):634.
5. Kalra K, Tomar P. Stem cell: basics, classification and applications. American Journal of Phytomedicine and Clinical Therapeutics. 2014;2(7):919-30.
6. Ullah M, Chaudhary V, Absar N. Study and analysis of stem cell therapy and its ethical consideration. Bangladesh Journal of Bioethics. 2010;1(3):22-34.
7. Rosen MR, Myerburg RJ, Francis DP, Cole GD, Marbán E. Translating stem cell research to cardiac disease therapies: pitfalls and prospects for improvement. Journal of the American College of Cardiology. 2014;64(9):922-37.
8. Stadtfeld M, Hochedlinger K. Induced pluripotency: history, mechanisms, and applications. Genes and development. 2010;24(20):2239-63.
9. Zheng YL. Some ethical concerns about human induced pluripotent stem cells. Science and engineering ethics. 2016; 22(5):1277-84.
10. Schenke-Layland K, MacLellan WR. Induced pluripotent stem cells: it’s like deja vu all over again. Circulation. 2009;120(15):1462-4.
11. Perin EC. Stem cell therapy for cardiovascular disease. Texas Heart Institute Journal. 2006;33(2):204.
12. Yu H, Lu K, Zhu J, Wang JA. Stem cell therapy for ischemic heart diseases. British Medical Bulletin. 2017;121(1):135-54.
13. Singh A, Singh A, Sen D. Mesenchymal stem cells in cardiac regeneration: a detailed progress report of the last 6 years (2010–2015). Stem cell research and therapy. 2016;7(1):82.
14. McDevitt TC, Laflamme MA, Murry CE. Proliferation of cardiomyocytes derived from human embryonic stem cells is mediated via the IGF/PI 3-kinase/Akt signaling pathway. Journal of molecular and cellular cardiology. 2005;39(6):865-73.
15. Avasthi S, Srivastava RN, Singh A, Srivastava M. Stem cell: past, present and future--a review article. Internet Journal of Medical Update. 2008;3(1):22-31.
16. Sun R, Li X, Liu M, Zeng Y, Chen S, Zhang P. Advances in stem cell therapy for cardiovascular disease. International journal of molecular medicine. 2016;38(1):23-9.
17. Calloni R, Cordero EA, Henriques JA, Bonatto D. Reviewing and updating the major molecular markers for stem cells. Stem cells and development. 2013;22(9):1455-76.
18. Michal KS and Emmanuel ST. Stem Cells: From mechanism to technologies. World scientific publishing Co. Pte. Ltd., Singapore.2012.
19. Fakoya AO, Omole AE, Otohinoyi DA. Clinical Trials in the Therapeutic Application of Embryonic and Adult Stem Cells for Cardiovascular Disease. Health Sciences. 2017;6(10):38-44.
20. Krause K, Schneider C, Kuck KH, Jaquet K. Stem cell therapy in cardiovascular disorders. Cardiovascular therapeutics. 2010;28(5): e101-10.
21. Thakker R, Yang P. Mesenchymal stem cell therapy for cardiac repair. Current treatment options in cardiovascular medicine. 2014;16(7):323.
22. Trivedi P, Tray N, Nguyen T, Nigam N, Gallicano GI. Mesenchymal stem cell therapy for treatment of cardiovascular disease: helping people sooner or later. Stem cells and development. 2010;19(7):1109-20.
23. Menasché P, Vanneaux V, Hagège A, Bel A, Cholley B, Cacciapuoti I, Parouchev A, Benhamouda N, Tachdjian G, Tosca L, Trouvin JH. Human embryonic stem cell-derived cardiac progenitors for severe heart failure treatment: first clinical case report. European heart journal. 2015;36(30):2011-7.
24. Taylor DA, Robertson MJ. Cardiovascular translational medicine (IX) the basics of cell therapy to treat cardiovascular disease: one cell does not fit all. Revista Española de Cardiología (English Edition). 2009;62(9):1032-44.
25. Borlongan CV, Kaneko Y, Maki M, Yu SJ, Ali M, Allickson JG, Sanberg CD, Kuzmin-Nichols N, Sanberg PR. Menstrual blood cells display stem cell–like phenotypic markers and exert neuroprotection following transplantation in experimental stroke. Stem cells and development. 2010;19(4):439-52
26. Rossignoli F, Caselli A, Grisendi G, Piccinno S, Burns JS, Murgia A, Veronesi E, Loschi P, Masini C, Conte P, Paolucci P. Isolation, characterization, and transduction of endometrial decidual tissue multipotent mesenchymal stromal/stem cells from menstrual blood. BioMed research international. 2013.
27. Delorme B, Ringe J, Gallay N, Le Vern Y, Kerboeuf D, Jorgensen C, Rosset P, Sensebe L, Layrolle P, Häupl T, Charbord P. Specific plasma membrane protein phenotype of culture-amplified and native human bone marrow mesenchymal stem cells. Blood. 2008;111(5):2631-5.
28. BÜHRING HJ, Battula VL, Treml S, Schewe B, Kanz L, Vogel W. Novel markers for the prospective isolation of human MSC. Annals of the New York Academy of Sciences. 2007;1106(1):262-71.
29. Min JY, Sullivan MF, Yang Y, Zhang JP, Converso KL, Morgan JP, Xiao YF. Significant improvement of heart function by cotransplantation of human mesenchymal stem cells and fetal cardiomyocytes in postinfarcted pigs. The Annals of thoracic surgery. 2002;74(5):1568-75.
30. Battula VL, Treml S, Abele H, Bühring HJ. Prospective isolation and characterization of mesenchymal stem cells from human placenta using a frizzled-9-specific monoclonal antibody. Differentiation. 2008;76(4):326-36.
31. Caplan AI. Mesenchymal stem cells: cell–based reconstructive therapy in orthopedics. Tissue engineering. 2005;11(7-8):1198-211.
32. Caplan AI. Why are MSCs therapeutic? New data: new insight. The Journal of Pathology: A Journal of the Pathological Society of Great Britain and Ireland. 2009; 217(2):318-24.
33. Caplan AI, Correa D. PDGF in bone formation and regeneration: new insights into a novel mechanism involving MSCs. Journal of Orthopaedic Research. 2011;29(12):1795-803.
34. Toma C, Pittenger MF, Cahill KS, Byrne BJ, Kessler PD. Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. Circulation. 2002;105(1):93-8.
35. Morrison SJ, Scadden DT. The bone marrow niche for haematopoietic stem cells. Nature. 2014 ;505(7483):327.
36. Balmer GM, Riley PR. Harnessing the potential of adult cardiac stem cells: lessons from haematopoiesis, the embryo and the niche. Journal of cardiovascular translational research. 2012;5(5):631-40.
37. Abbott JD, Giordano FJ. Stem cells and cardiovascular disease. Journal of nuclear cardiology. 2003;10(4):403-12.
38. Dimmeler S, Burchfield J, Zeiher AM. Cell-based therapy of myocardial infarction. Arteriosclerosis, thrombosis, and vascular biology. 2008;28(2):208-16.
39. Patel AN, Geffner L, Vina RF, Saslavsky J, Urschel Jr HC, Kormos R, Benetti F. Surgical treatment for congestive heart failure with autologous adult stem cell transplantation: a prospective randomized study. The Journal of thoracic and cardiovascular surgery. 2005 ;130(6):1631-8.
40. Stamm C, Kleine HD, Choi YH, Dunkelmann S, Lauffs JA, Lorenzen B, David A, Liebold A, Nienaber C, Zurakowski D, Freund M. Intramyocardial delivery of CD133+ bone marrow cells and coronary artery bypass grafting for chronic ischemic heart disease: safety and efficacy studies. The Journal of thoracic and cardiovascular surgery. 2007;133(3):717-25.
41. Perin EC, Silva GV, Zheng Y, Gahremanpour A, Canales J, Patel D, Fernandes MR, Keller LH, Quan X, Coulter SA, Moore WH. Randomized, double-blind pilot study of transendocardial injection of autologous aldehyde dehydrogenase–bright stem cells in patients with ischemic heart failure. American heart journal. 2012;163(3):415-21.
42. Asahara T, Kalka C, Isner JM. Stem cell therapy and gene transfer for regeneration. Gene therapy. 2000;7(6):451.
43. Torrente Y. Advancements in stem cells treatment of skeletal muscle wasting. Frontiers in physiology. 2014; 5:48.
44. Chal J, Pourquie O. Making muscle: skeletal myogenesis in vivo and in vitro. Development. 2017;144(12):2104-22.
45. Hassan N, Tchao J, Tobita K. Concise review: skeletal muscle stem cells and cardiac lineage: potential for heart repair. Stem cells translational medicine. 2014;3(2):183-93.
46. Menasché P, Hagege AA, Vilquin JT, Desnos M, Abergel E, Pouzet B, Bel A, Sarateanu S, Scorsin M, Schwartz K, Bruneval P. Autologous skeletal myoblast transplantation for severe postinfarction left ventricular dysfunction. Journal of the American College of Cardiology. 2003;41(7):1078-83.
47. Siminiak T, Fiszer D, Jerzykowska O, Grygielska B, Rozwadowska N, Kałmucki P, Kurpisz M. Percutaneous trans-coronary-venous transplantation of autologous skeletal myoblasts in the treatment of post-infarction myocardial contractility impairment: the POZNAN trial. European Heart Journal. 2005;26(12):1188-95.
48. Pagani FD, DerSimonian H, Zawadzka A, Wetzel K, Edge AS, Jacoby DB, Dinsmore JH, Wright S, Aretz TH, Eisen HJ, Aaronson KD. Autologous skeletal myoblasts transplanted to ischemia-damaged myocardium in humans: histological analysis of cell survival and differentiation. Journal of the American College of Cardiology. 2003;41(5):879-88.
49. Linke A, Müller P, Nurzynska D, Casarsa C, Torella D, Nascimbene A, Castaldo C, Cascapera S, Böhm M, Quaini F, Urbanek K. Stem cells in the dog heart are self-renewing, clonogenic, and multipotent and regenerate infarcted myocardium, improving cardiac function. Proceedings of the National Academy of Sciences. 2005;102(25):8966-71.
50. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131(5):861-72.
51. Dominici ML, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini FC, Krause DS, Deans RJ, Keating A, Prockop DJ, Horwitz EM. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006 ;8(4):315-7.
52. Haider HK, Jiang S, Idris NM, Ashraf M. IGF-1–overexpressing mesenchymal stem cells accelerate bone marrow stem cell mobilization via paracrine activation of SDF-1α/CXCR4 signaling to promote myocardial repair. Circulation research. 2008;103(11):1300-8.
53. Dzhoyashvili NA, Efimenko AY, Kochegura TN, Kalinina NI, Koptelova NV, Sukhareva OY, Shestakova MV, Akchurin RS, Tkachuk VA, Parfyonova YV. Disturbed angiogenic activity of adipose-derived stromal cells obtained from patients with coronary artery disease and diabetes mellitus type 2. Journal of translational medicine. 2014;12(1):337.
54. Bolli R, Chugh AR, D'Amario D, Loughran JH, Stoddard MF, Ikram S, Beache GM, Wagner SG, Leri A, Hosoda T, Sanada F. Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial. The Lancet. 2011 ;378(9806):1847-57.
55. Matsuura K, Nagai T, Nishigaki N, Oyama T, Nishi J, Wada H, Sano M, Toko H, Akazawa H, Sato T, Nakaya H. Adult cardiac Sca-1-positive cells differentiate into beating cardiomyocytes. Journal of Biological Chemistry. 2004 ;279(12):11384-91.
56. Bu L, Jiang X, Martin-Puig S, Caron L, Zhu S, Shao Y, Roberts DJ, Huang PL, Domian IJ, Chien KR. Human ISL1 heart progenitors generate diverse multipotent cardiovascular cell lineages. Nature. 2009;460(7251):113.
57. Pfister O, Mouquet F, Jain M, Summer R, Helmes M, Fine A, Colucci WS, Liao R. CD31− but not CD31+ cardiac side population cells exhibit functional cardiomyogenic differentiation. Circulation research. 2005;97(1):52-61.
58. Cai CL, Martin JC, Sun Y, Cui L, Wang L, Ouyang K, Yang L, Bu L, Liang X, Zhang X, Stallcup WB. A myocardial lineage derives from Tbx18 epicardial cells. Nature. 2008;454(7200):104.
59. Galvez BG, Sampaolesi M, Barbuti A, Crespi A, Covarello D, Brunelli S, Dellavalle A, Crippa S, Balconi G, Cuccovillo I, Molla F. Cardiac mesoangioblasts are committed, self-renewable progenitors, associated with small vessels of juvenile mouse ventricle. Cell death and differentiation. 2008 ;15(9):1417.
60. Messina E, De Angelis L, Frati G, Morrone S, Chimenti S, Fiordaliso F, Salio M, Battaglia M, Latronico MV, Coletta M, Vivarelli E. Isolation and expansion of adult cardiac stem cells from human and murine heart. Circulation research. 2004;95(9):911-21.
61. Fischer KM, Cottage CT, Wu W, Din S, Gude NA, Avitabile D, Quijada P, Collins BL, Fransioli J, Sussman MA. Enhancement of Myocardial Regeneration Through Genetic Engineering of Cardiac Progenitor Cells Expressing Pim-1 Kinase. Circulation. 2009; 120(21):2077-87.
62. Angert D, Berretta RM, Kubo H, Zhang H, Chen X, Wang W, Ogorek B, Barbe M, Houser SR. Repair of the injured adult heart involves new myocytes potentially derived from resident cardiac stem cells. Circulation research. 2011;108(10):1226-37.
63. Makkar RR, Smith RR, Cheng KE, Malliaras K, Thomson LE, Berman D, Czer LS, Marbán L, Mendizabal A, Johnston PV, Russell SD. Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomised phase 1 trial. The Lancet. 2012;379(9819):895-904.
64. Smith RR, Marbán E, Marbán L. Enhancing retention and efficacy of cardiosphere-derived cells administered after myocardial infarction using a hyaluronan-gelatin hydrogel. Biomatter. 2013; 3(1):e24490.
65. Bonios M, Chang CY, Pinheiro A, Dimaano VL, Higuchi T, Melexopoulou C, Bengel F, Terrovitis J, Abraham TP, Abraham MR. Cardiac resynchronization by cardiosphere-derived stem cell transplantation in an experimental model of myocardial infarction. Journal of the American Society of Echocardiography. 2011; 24(7):808-14.
66. Miyahara Y. Nagaya N, Kataoka M, Yanagawa B, Tanaka K, Hao H, Ishino K, Ishida H, Shimizu T, Kangawa K, Sano S, Okano T, Kitamura S, Mori H. Monolayered mesenchymal stem cells repair scarred myocardium after myocardial infarction. Nat Med. 2006; 12:459-65.
67. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126(4):663-76.
68. Dib N, Menasche P, Bartunek JJ, Zeiher AM, Terzic A, Chronos NA, Henry TD, Peters NS, Fernández-Avilés F, Yacoub M, Sanborn TA. Recommendations for successful training on methods of delivery of biologics for cardiac regeneration: a report of the International Society for Cardiovascular Translational Research. JACC: Cardiovascular Interventions. 2010 ;3(3):265-75.
69. Reisman M, Adams KT. Stem cell therapy: A look at current research, regulations, and remaining hurdles. Pharmacy and Therapeutics. 2014 ;39(12):846
70. Ahmadian E, Eftekhari A, Khosroushahi AY. Current Research of the Renin-Angiotensin System Effect on Stem Cell Therapy. InRenin-Angiotensin System-Past, Present and Future 2017.9:159-71.
71. Chan EC, Jiang F, Peshavariya HM, Dusting GJ. Regulation of cell proliferation by NADPH oxidase-mediated signaling: potential roles in tissue repair, regenerative medicine and tissue engineering. Pharmacology and therapeutics. 2009;122(2):97-108.
72. Schenke‐Layland K, Rhodes KE, Angelis E, Butylkova Y, Heydarkhan‐Hagvall S, Gekas C, Zhang R, Goldhaber JI, Mikkola HK, Plath K, MacLellan WR. Reprogrammed mouse fibroblasts differentiate into cells of the cardiovascular and hematopoietic lineages. Stem cells. 2008;26(6):1537-46.
73. Mauritz C, Schwanke K, Reppel M, Neef S, Katsirntaki K, Maier LS, Nguemo F, Menke S, Haustein M, Hescheler J, Hasenfuss G. Generation of functional murine cardiac myocytes from induced pluripotent stem cells. Circulation. 2008 ;118(5):507.
74. Narazaki G, Uosaki H, Teranishi M, Okita K, Kim B, Matsuoka S, Yamanaka S, Yamashita JK “Directed and systematic differentiation of cardiovascular cells from mouse induced pluripotent stem cells.” Circulation. 2008 ;118(5):498-506.
75. Zwi L, Caspi O, Arbel G, Huber I, Gepstein A, Park IH, Gepstein L. Cardiomyocyte differentiation of human induced pluripotent stem cells. Circulation. 2009 ;120(15):1513.
76. https://www.tctmd.com/news/ischemic-heart-disease-leading-cause-death-globally/
77. https://www.medicalnewstoday.com/articles/184130.php
78. Weir RA, McMurray JJ. Epidemiology of heart failure and left ventricular dysfunction after acute myocardial infarction. Current heart failure reports. 2006 ;3(4):175-80.
79. Anversa P, Nadal-Ginard B. Myocyte renewal and ventricular remodelling. Nature. 2002 ;415(6868):240.
80. Jameel MN, Zhang J. Stem cell therapy for ischemic heart disease. Antioxidants and redox signaling. 2010 ;13(12):1879-97.
81. Tsilimigras DI, Oikonomou EK, Moris D, Schizas D, Economopoulos KP, Mylonas KS. Stem cell therapy for congenital heart disease: a systematic review. Circulation. 2017 ;136(24):2373-85.
82. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG. Inter-society consensus for the management of peripheral arterial disease (TASC II). Journal of vascular surgery. 2007 ;45(1): S5-67.
83. Olin JW, White CJ, Armstrong EJ, Kadian-Dodov D, Hiatt WR. Peripheral artery disease: evolving role of exercise, medical therapy, and endovascular options. Journal of the American College of Cardiology. 2016;67(11):1338-57.
84. Tateishi-Yuyama E, Matsubara H, Murohara T, Ikeda U, Shintani S, Masaki H, Amano K, Kishimoto Y, Yoshimoto K, Akashi H, Shimada K. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial. The Lancet. 2002 ;360(9331):427-35.
85. Wehman B, Kaushal S. The emergence of stem cell therapy for patients with congenital heart disease. Circulaton research. 2015;116(4):566-69.
86. Blue GM, Kirk EP, Sholler GF, Harvey RP, Winlaw DS. Congenital heart disease: current knowledge about causes and inheritance. The Medical Journal of Australia. 2012 ;197(3):155-9.
87. Avolio E, Caputo M, Madeddu P. Stem cell therapy and tissue engineering for correction of congenital heart disease. Frontiers in cell and developmental biology. 2015;3:39.
88. Stone J, Hangge P, Albadawi H, Wallace A, Shamoun F, Knuttien MG, Naidu S, Oklu R. Deep vein thrombosis: pathogenesis, diagnosis, and medical management. Cardiovascular diagnosis and therapy. 2017 ;7(Suppl 3):S276.
89. Ruggeri ZM. Von Willebrand factor, platelets and endothelial cell interactions. Journal of Thrombosis and Haemostasis. 2003 ;1(7):1335-42.
90. Schreijer AJ, Reitsma PH, Cannegieter SC. High hematocrit as a risk factor for venous thrombosis. Cause or innocent bystander?.2010;95(2):182-4.
91. Wadajkar AS, Santimano S, Rahimi M, Yuan B, Banerjee S, Nguyen KT. Deep vein thrombosis: Current status and nanotechnology advances. Biotechnology advances. 2013 ;31(5):504-13.
92. Galson SK. Prevention of deep vein thrombosis and pulmonary embolism. Public Health Reports. 2008;123(4):420-1.
93. Jung JW, Kwon M, Choi JC, Shin JW, Park IW, Choi BW, Kim JY. Familial occurrence of pulmonary embolism after intravenous, adipose tissue-derived stem cell therapy. Yonsei medical journal. 2013;54(5):1293-6.
94. Natasha Kekre, Haesook T. Kim, Vincent T. Ho, Corey S Cutler, Philippe Armand, Sarah Nikiforow, Edwin P. Alyea, Robert J. Soiffer, Joseph H Antin, Jean M. Connors, John Koreth. Venous Thromboembolism Is Associated with Graft-Versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation. Blood. 2015;126(23):742-8.
95. Patel AN, Geffner L, Vina RF, Saslavsky J, Urschel Jr HC, Kormos R, Benetti F. Surgical treatment for congestive heart failure with autologous adult stem cell transplantation: a prospective randomized study. The Journal of thoracic and cardiovascular surgery. 2005 ;130(6):1631-8.
96. Pompilio G, Steinhoff G, Liebold A, Pesce M, Alamanni F, Capogrossi MC, Biglioli P. Direct minimally invasive intramyocardial injection of bone marrow-derived AC133+ stem cells in patients with refractory ischemia: preliminary results. The Thoracic and cardiovascular surgeon. 2008 ;56(02):71-6.
97. Sheng CC, Zhou L, Hao J. Current stem cell delivery methods for myocardial repair. BioMed research international. 2013;2013.
98. Halkos ME, Zhao ZQ, Kerendi F, Wang NP, Jiang R, Schmarkey LS, Martin BJ, Quyyumi AA, Few WL, Kin H, Guyton RA. Intravenous infusion of mesenchymal stem cells enhances regional perfusion and improves ventricular function in a porcine model of myocardial infarction. Basic research in cardiology. 2008;103(6):525-36.
99. Hare JM, Traverse JH, Henry TD, Dib N, Strumpf RK, Schulman SP, Gerstenblith G, DeMaria AN, Denktas AE, Gammon RS, Hermiller JB. A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. Journal of the American College of Cardiology. 2009;54(24):2277-86.
100. https://clinicaltrials.gov/ct2/show/NCT00877903
101. Dib N, Khawaja H, Varner S, McCarthy M, Campbell A. Cell therapy for cardiovascular disease: a comparison of methods of delivery. Journal of cardiovascular translational research. 2011 ;4(2):177-81.
102. Norol F, Merlet P, Isnard R, Sebillon P, Bonnet N, Cailliot C, Carrion C, Ribeiro M, Charlotte F, Pradeau P, Mayol JF. Influence of mobilized stem cells on myocardial infarct repair in a nonhuman primate model. Blood. 2003;102(13):4361-8.
103. Powell TM, Paul JD, Hill JM, Thompson M, Benjamin M, Rodrigo M, McCoy JP, Read EJ, Khuu HM, Leitman SF, Finkel T. Granulocyte colony-stimulating factor mobilizes functional endothelial progenitor cells in patients with coronary artery disease. Arteriosclerosis, thrombosis, and vascular biology. 2005;25(2):296-301.